ROCKVILLE, Md., July 15, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share […]
Synthetic Biologics Announces Reverse Stock Split Read More »
-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing antibodies- – Reported positive safety data on SYN-020 intestinal alkaline phosphatase from the Phase 1 Multiple Ascending Dose
-Completed acquisition of VCN Biosciences, expanding pipeline into oncology- -VCN-01 received Orphan Drug Designation for retinoblastoma from the U.S. FDA- -As of December 31, 2021, Synthetic Biologics reports $67.3 million in cash, which is expected to provide runway through the end of 2023- -Conference call and webcast to be held today at 4:30 p.m. ET-
Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results Read More »
ROCKVILLE, Md., Jan. 26, 2022 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that the Company will be presenting at the B. Riley Securities Oncology Conference being held virtually on January 27-28, 2022. Steven Shallcross, Chief Executive Officer and Chief
Lead drug candidate VCN-01 demonstrated clinical activity in multiple Phase 1 clinical trials Designed for systemic delivery, high selectivity, and enhanced tumor access VCN-01 granted Orphan Drug Designation in Pancreatic Cancer by the EMA Synthetic Biologics and VCN Biosciences to host a conference call today, December 14th, at 10:00 a.m. Eastern Time ROCKVILLE, Md., Dec.
Webcast 3 2021 Quarterly Results PDF Release AUDIO Webcast PDF HTML 10-Q Filing ZIP XLS HTML XBRL
Third Quarter 2021 Operational Highlights and Financial Results Conference Call Read More »
Initiated a Phase 1 Multiple Ascending Dose Clinical Trial of SYN-020 in Healthy Adult Volunteers; Topline Data Readout Expected in Q2 2022 Enrollment Remains Ongoing in Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients Reports $72.1 Million of Cash on Hand to Fund Clinical Programs Through Key Milestones Beyond 2022 ROCKVILLE, Md., Nov.
— Conference Call Scheduled for Wednesday, November 3, 2021 at 4:30 p.m. ET — ROCKVILLE, Md., Oct. 26, 2021 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company
Phase 1 Single-Ascending Dose Clinical Trial of SYN-020 Demonstrated Favorable Safety Profile and was Well Tolerated at All Dose Levels; A Second Phase 1 Multiple-Ascending Dose Clinical Trial Expected to Commence in Q3 2021 Enrollment in Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic HCT Recipients Proceeding as Planned Reports $74.3 Million of Cash on
